PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Zeng, Jian
Wang, Guoqiang
Yan, Zhengqing
Zheng, Hao
Li, Jianqiang
Tao, Feng
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
[3] Wen Zhou Med Univ, Lishui Peoples Hosp, Dept Resp Med, Affiliated Hosp 6, Lishui, Peoples R China
[4] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[5] Jiaxing Univ, Dept Resp Med, Affiliated Hosp, Jiaxing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15112
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer
    Zhang, Wenjing
    Shi, Fuyan
    Kong, Yujia
    Li, Yuting
    Sheng, Chao
    Wang, Suzhen
    Wang, Qinghua
    CANCER MEDICINE, 2022, 11 (03): : 676 - 691
  • [2] PTPRD: A Positive Predictive Biomarker for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
    Shen, J.
    Zhou, H.
    Liu, J.
    Zhang, Y.
    Zhou, T.
    Hong, S.
    Zhao, Y.
    Yang, Y.
    Zhao, H.
    Huang, Y.
    Fang, W.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S335 - S336
  • [3] Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC).
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao V.
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [5] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [6] Neutrophil-to-lymphocyte ratio as a response predictor to immune checkpoint inhibitors in non-small cell lung cancer
    Amorim Costa, C.
    Pires, M. R.
    Monteiro, J. C.
    Caetano, A. C.
    Salgueiro, F. R.
    Correia Magalhaes, J.
    de Sousa, M. J. P.
    Basto, R.
    Meira Garcia, A. R.
    Domingues, I.
    Jesus, E.
    Sousa, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S768 - S768
  • [7] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
    Gargalionis, Antonios N.
    Papavassiliou, Kostas A.
    Papavassiliou, Athanasios G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [8] Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)
    Cardona, A. F.
    Arrieta, O.
    Ruiz-Patino, A.
    Zatarain Barron, L.
    Corrales-Rodriguez, L.
    Martin, C.
    Barron, F.
    Sotelo, C.
    Rodriguez, J.
    Ricaurte, L.
    Freitas, H.
    Cordeiro De Lima, V. C.
    Mas, L.
    Avila, J.
    Mayorga, D.
    Archila, P.
    Otero, J.
    Carranza, H.
    Vargas, C.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1171 - S1171
  • [9] Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC)
    Desai, Aakash
    Subbiah, Vivek
    Dimou, Anastasios
    Deshane, Jessy
    Goliwas, Kayla
    Ponnazhagan, Selvarangan
    Das, Devika Govind
    Khalil, Maya
    Lo, Ying-Chun
    Lin, Edwin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Alfranca, Yolanda Lage
    Garcia, Maria Eugenia Olmedo
    Rueda, Ana Gomez
    Ballesteros, Pablo Alvarez
    Rodriguez, Diana Rosero
    Velasco, Marisa Torres
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
12345